Chauche Thierry 4

What Happened

• Thierry Chauche, Chief Financial Officer of Sagimet Biosciences (SGMT), received equity awards on February 19, 2026. The filing shows (1) 44,000 restricted stock units (RSUs) granted at $0.00 and (2) 88,000 derivative awards granted at $0.00 (totaling 132,000 awards). These are grants/awards (Form 4 transaction code A), not open-market purchases or sales, so there was no cash transaction reported.

Key Details

• Transaction date: 2026-02-19; Form 4 filed 2026-02-20 (timely filing).
• Grants: 44,000 RSUs (@ $0.00) and 88,000 derivative awards (@ $0.00); total granted = 132,000 awards; reported value $0 on grant.
• Vesting: RSUs vest in four equal annual installments beginning Feb 19, 2026 (F1). The 88,000 derivative awards vest/are exercisable over 48 equal monthly installments following Feb 19, 2026 (F2). Both are subject to continued service.
• Shares owned after transaction: not disclosed in the provided filing details.
• Transaction code: A = Award/Grant. No 10b5-1 plan, tax-withholding, or late-filing indication was reported in the information provided.

Context

• These awards are time-based equity grants subject to multi-year vesting; they do not represent an immediate sale or market purchase. The derivative portion appears to be option-like and will vest monthly (F2); the RSUs convert to shares only upon vesting (F1). Such grants are common for executive compensation and align future pay with continued service and company performance; they do not by themselves indicate the insider is buying or selling stock today.